Lifecell Corp - Amended Statement of Ownership: Solicitation (SC 14D9/A)
April 30 2008 - 4:43PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
LIFECELL CORPORATION
(Name of Subject Company)
LIFECELL CORPORATION
(Name of Person Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
531927101
(CUSIP Number of Class of
Securities)
Paul G. Thomas
Chairman of the Board, President and Chief Executive Officer
LifeCell Corporation
One Millennium Way
Branchburg, New
Jersey 08876
(908) 947-1100
(Name, address and telephone number of person authorized to receive
notice and communications on behalf of the person
filing statement)
Copies to:
Alan Wovsaniker, Esq.
Steven M. Skolnick, Esq.
Lowenstein Sandler PC
65 Livingston
Avenue
Roseland, NJ 07068
(973) 597-2500
¨
|
Check the box if the filing relates to preliminary communications made before the commencement date of a tender offer.
|
Introduction
This Amendment No. 3 to Schedule 14D-9 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (the
Schedule 14D-9
) originally filed with the U.S. Securities and Exchange Commission (the
SEC
) by LifeCell Corporation, a Delaware corporation (the
Company
), on April 21, 2008, as amended by Amendment No. 1 to the Schedule 14D-9 filed with the SEC by the Company on April 21, 2008 and
Amendment No. 2 to the Schedule 14D-9 filed with the SEC by the Company on April 25, 2008. Except as otherwise noted, the information set forth in the original Schedule 14D-9 remains unchanged. Capitalized terms used but not defined herein
have the meaning ascribed to them in the Schedule 14D-9.
ITEM 8.
|
ADDITIONAL INFORMATION
|
Item 8 is hereby amended and supplemented by adding the following paragraph at the end of the subsection entitled Regulatory Approvals:
On April 29, 2008, the Company was notified that early termination of the waiting period applicable to the Offer and the Merger under the HSR Act had been granted. Accordingly, the condition to the Offer
relating to the expiration or termination of the applicable HSR Act waiting period has been satisfied.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
LIFECELL CORPORATION
|
|
|
By:
|
|
/s/ Steven T. Sobieski
|
|
|
Steven T. Sobieski
|
|
|
Chief Financial Officer
|
Date: April 30, 2008
Lifecell Corp (MM) (NASDAQ:LIFC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lifecell Corp (MM) (NASDAQ:LIFC)
Historical Stock Chart
From Oct 2023 to Oct 2024